<DOC>
	<DOCNO>NCT01026558</DOCNO>
	<brief_summary>The primary objective study compare pharmacokinetics ( drug absorb body , distribute within body remove body time ) ceftobiprole morbidly obese patient non-obese patient . The secondary objective assess pharmacodynamics ( study action effect drug body ) ass safety tolerability ceftobiprole order support dose recommendation morbidly obese population .</brief_summary>
	<brief_title>A Study Evaluating Pharmacokinetics Ceftobiprole When Taken Obese Patients</brief_title>
	<detailed_description>This open-label ( people involve know identity intervention ) , parallel-group , Phase 1 study morbidly obese non-obese men woman . A total 25 patient ( 12 morbidly obese 13 non-obese ) patient enrol study . Morbidly obese nonobese patient match individually 1:1 age ( Â±10 year ) , sex , renal function ( define creatinine level urine ) . There 4 phase clinical study : pretreatment ( screening/baseline ) phase 21 day ; 2-day open-label treatment phase patient receive single 2-hour intravenous ( directly vein ) infusion ceftobiprole 500 mg follow multiple ( 15 ) blood urine sample draw 24 hour follow study drug administration ; follow-up phase approximately 1 week last blood sample patient monitor telephone development new adverse event assessment ongoing adverse event . Each patient receive single 2-hour infusion ( directly vein ) ceftobiprole 500 mg</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Body mass index ( BMI ) =or &gt; 40 kg/m2 normal BMI 1830 Blood pressure 90140 mm Nonsmoker History medically significant illness Uncontrolled hypertension Uncontrolled high blood cholesterol triglyceride</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Obesity , Ceftobiprole</keyword>
	<keyword>Skin Infections</keyword>
	<keyword>Staphylococcal Skin Infections</keyword>
	<keyword>Bacterial Skin Infections</keyword>
	<keyword>Streptococcal Infection</keyword>
</DOC>